JP2010525042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010525042A5 JP2010525042A5 JP2010504828A JP2010504828A JP2010525042A5 JP 2010525042 A5 JP2010525042 A5 JP 2010525042A5 JP 2010504828 A JP2010504828 A JP 2010504828A JP 2010504828 A JP2010504828 A JP 2010504828A JP 2010525042 A5 JP2010525042 A5 JP 2010525042A5
- Authority
- JP
- Japan
- Prior art keywords
- sapacitabine
- days
- treatment cycle
- administered
- metabolite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LBGFKUUHOPIEMA-PEARBKPGSA-N sapacitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 LBGFKUUHOPIEMA-PEARBKPGSA-N 0.000 claims 44
- 229950006896 sapacitabine Drugs 0.000 claims 44
- 201000005962 mycosis fungoides Diseases 0.000 claims 26
- 239000002207 metabolite Substances 0.000 claims 24
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 19
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 19
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000002062 proliferating effect Effects 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- 230000001988 toxicity Effects 0.000 claims 5
- 231100000419 toxicity Toxicity 0.000 claims 5
- 208000009359 Sezary Syndrome Diseases 0.000 claims 4
- 208000021388 Sezary disease Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0708021A GB0708021D0 (en) | 2007-04-25 | 2007-04-25 | Use |
| GB0708021.1 | 2007-04-25 | ||
| GB0723723.3 | 2007-12-04 | ||
| GB0723723A GB0723723D0 (en) | 2007-12-04 | 2007-12-04 | Use |
| PCT/GB2008/001424 WO2008132443A1 (en) | 2007-04-25 | 2008-04-24 | Use of sapacitabine to treat proliferative disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014170018A Division JP5892565B2 (ja) | 2007-04-25 | 2014-08-25 | 増殖性疾患を治療するためのサパシタビンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010525042A JP2010525042A (ja) | 2010-07-22 |
| JP2010525042A5 true JP2010525042A5 (enExample) | 2011-06-02 |
| JP5852309B2 JP5852309B2 (ja) | 2016-02-03 |
Family
ID=39719125
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010504828A Expired - Fee Related JP5852309B2 (ja) | 2007-04-25 | 2008-04-24 | 増殖性疾患を治療するためのサパシタビンの使用 |
| JP2014170018A Expired - Fee Related JP5892565B2 (ja) | 2007-04-25 | 2014-08-25 | 増殖性疾患を治療するためのサパシタビンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014170018A Expired - Fee Related JP5892565B2 (ja) | 2007-04-25 | 2014-08-25 | 増殖性疾患を治療するためのサパシタビンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8536188B2 (enExample) |
| EP (1) | EP2148676B1 (enExample) |
| JP (2) | JP5852309B2 (enExample) |
| ES (1) | ES2587381T3 (enExample) |
| PL (1) | PL2148676T3 (enExample) |
| WO (1) | WO2008132443A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| US8536188B2 (en) | 2007-04-25 | 2013-09-17 | Cyclacel Limited | Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine |
| JP2011520845A (ja) * | 2008-05-15 | 2011-07-21 | カソリック ユニヴェルシテイト ルーヴェン，ケー．ユー． ルーヴェン アール アンド ディー | 抗癌剤の組合せによる治療 |
| EP2696878B1 (en) | 2011-04-14 | 2019-07-10 | Cyclacel Limited | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
| EP2874631A1 (en) * | 2012-05-15 | 2015-05-27 | Cyclacel Limited | Dosage regimen for sapacitabine and seliciclib |
| US20150335637A1 (en) * | 2013-01-07 | 2015-11-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cutaneous t cell lymphoma |
| WO2021079129A1 (en) | 2019-10-24 | 2021-04-29 | Cyclacel Limited | Dosing regimen |
| US11957701B2 (en) | 2020-07-17 | 2024-04-16 | Delta-Fly Pharma, Inc. | Therapy and new therapeutic agent for blood cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040101274A (ko) * | 2002-03-08 | 2004-12-02 | 노파르티스 아게 | 에포틸론 유도체 및 알킬화제를 포함하는 병용 제제 |
| US20050014716A1 (en) * | 2003-05-21 | 2005-01-20 | Wang Jin Wei | Pancreatic cancer treatment |
| KR20070090943A (ko) * | 2004-12-21 | 2007-09-06 | 쉐링 코포레이션 | 항종양제로서 신규한 파르네실 단백질 트랜스퍼라제 억제제 |
| PT1849470T (pt) * | 2005-01-26 | 2017-09-22 | Taiho Pharmaceutical Co Ltd | Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase |
| CA2617623A1 (en) * | 2005-08-18 | 2007-02-22 | Victoria M. Richon | Combination methods of saha and targretin for treating cancer |
| GB0526419D0 (en) * | 2005-12-23 | 2006-02-08 | Cyclacel Ltd | Formulation |
| GB0609530D0 (en) * | 2006-05-12 | 2006-06-21 | Cyclacel Ltd | Combination |
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| US8536188B2 (en) | 2007-04-25 | 2013-09-17 | Cyclacel Limited | Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine |
-
2008
- 2008-04-24 US US12/597,293 patent/US8536188B2/en not_active Expired - Fee Related
- 2008-04-24 PL PL08737080.5T patent/PL2148676T3/pl unknown
- 2008-04-24 JP JP2010504828A patent/JP5852309B2/ja not_active Expired - Fee Related
- 2008-04-24 ES ES08737080.5T patent/ES2587381T3/es active Active
- 2008-04-24 WO PCT/GB2008/001424 patent/WO2008132443A1/en not_active Ceased
- 2008-04-24 EP EP08737080.5A patent/EP2148676B1/en active Active
-
2013
- 2013-08-15 US US13/967,901 patent/US9675631B2/en not_active Expired - Fee Related
-
2014
- 2014-08-25 JP JP2014170018A patent/JP5892565B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010525042A5 (enExample) | ||
| JP2025020147A5 (enExample) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2012509889A5 (enExample) | ||
| RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ | |
| JP2009539769A5 (enExample) | ||
| RU2013102398A (ru) | Лечение рака крови | |
| JP2012521435A5 (enExample) | ||
| JP2009518441A5 (enExample) | ||
| CN102753176B (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| JP2019526595A5 (enExample) | ||
| JP2011529968A5 (enExample) | ||
| JP2020528455A5 (enExample) | ||
| JP2006513184A5 (enExample) | ||
| JP2018522028A5 (enExample) | ||
| JP2024016209A5 (enExample) | ||
| JP2013541587A5 (enExample) | ||
| JP2017537927A5 (enExample) | ||
| RU2346686C2 (ru) | Комбинации, включающие эпотилоны и антиметаболиты | |
| JP2013540734A5 (enExample) | ||
| JP2018506533A5 (enExample) | ||
| JP2006503095A5 (enExample) | ||
| JP2007534634A5 (enExample) | ||
| JP2014510780A5 (enExample) | ||
| JPWO2020160527A5 (enExample) |